DCR-PHXC
- CAS No.
- 2266591-83-5
- Chemical Name:
- DCR-PHXC
- Synonyms
- DCR-PHXC;Nedosiran
- CBNumber:
- CB711075955
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| FDA UNII | 13U9R5J3WL |
|---|
DCR-PHXC Chemical Properties,Uses,Production
Uses
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate[1][2][3].
in vivo
Nedosiran is a RNAi therapy for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase[3].
Nedosiran specially inhibits hepatic expression of lactate dehydrogenase (LDHA)[3].
Nedosiran is a double-strand siRNA molecule that is conjugated with GalNAc, which takes advantage of the aforementioned unique asialoglycoprotein receptor (ASGPR) delivery system in the liver. Nedosiran is administered by monthly subcutaneous injection. Nedosiran decreases plasma oxalate in animal models[3].
References
[1] Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149. DOI:10.1016/j.urology.2021.03.014
[2] Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep.?2021 Feb 3;6(4):1088-1098. DOI:10.1016/j.ekir.2021.01.029
[3] Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol.?2021 May 22. DOI:10.1111/bcp.14925
DCR-PHXC Preparation Products And Raw materials
Raw materials
Preparation Products
DCR-PHXC Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | orders@jknbiochem.com | China | 5221 | 58 |
| Nugene Biopharm Science (Hangzhou) Co., Ltd. | 13326014885 | service@nugene.com.cn | China | 55 | 58 |
| Jiangsu Magic Biotechnology Co., Ltd | 13921770081 | svp01@magicbiotech.cn | China | 491 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 6195 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 13823398779 13823398779 | 3062105966@qq.com | China | 3437 | 58 |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525; 17316404525 | 209533805@qq.com | China | 9976 | 58 |